Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107656 | 0.83 | REN (0.42) | RENTSHRHTR2A | |
| SCHEMBL12333228 | 0.83 | TSHR (0.39) | RENTSHRCHRM1POLBTP53 | |
| SCHEMBL12110302 | 0.82 | REN (0.40) | RENTSHRKDM4E | |
| SCHEMBL12110136 | 0.79 | TSHR (0.42) | RENTSHRCHRM1POLBTP53 | |
| SCHEMBL12110145 | 0.77 | CHRM1 (0.35) | CHRM1DRD2CHRM5CHRM3 | |
| SCHEMBL12110103 | 0.77 | UTS2R (0.40) | TSHRCHRM1POLBTHRBKDM4E | |
| SCHEMBL12107648 | 0.77 | HTR2C (0.42) | TSHRHTR2A | |
| SCHEMBL12110391 | 0.75 | GRIN1 (0.34) | CHRM1DRD2CHRM5CHRM3 | |
| SCHEMBL12105721 | 0.73 | CHRM1 (0.40) | TSHRCHRM1POLBCHRM5CHRM3 | |
| SCHEMBL12110155 | 0.72 | TSHR (0.44) | RENTSHRCHRM1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | REN 1554/4885TSHR 3270/4885CHRM1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.